Mood Disorders in the News.
This section offers news briefs on U.S. Food and Drug Administration (FDA) decisions and issues associated with psychiatric treatments as of May 2024. The FDA has approved Rejoyn for the treatment of major depressive disorder (MDD) symptoms. Results of a study showed the effectiveness of lumateperon...
| Publicado en: | Psychiatric Times Vol. 41; no. 5; pp. 7 - 9 |
|---|---|
| Autor principal: | |
| Formato: | Artículo |
| Publicado: |
MJH Life Sciences
May2024
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |